Salvage treatment with apatinib for advanced non-small-cell lung cancer

No definitive chemotherapeutic regimen has been established in patients with non-small-cell lung cancer (NSCLC) who failed second- or third-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, in advanced NSCLC as salvage treatment. We evaluated the efficacy and toxic...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2017-01, Vol.10, p.1821-1825
Main Authors: Song, Zhengbo, Yu, Xinmin, Lou, Guangyuan, Shi, Xun, Zhang, Yiping
Format: Article
Language:English
Subjects:
Analysis
Antineoplastic agents
Binding sites
Cancer therapies
Care and treatment
Chemotherapy
Development and progression
Drug dosages
Drug therapy
Gastric cancer
Kinases
Lung cancer
Metastasis
Methods
Mutation
Non-small cell lung cancer
Non-small cell lung carcinoma
Original Research
Patient outcomes
Patients
Statistical analysis
Survival analysis
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:No definitive chemotherapeutic regimen has been established in patients with non-small-cell lung cancer (NSCLC) who failed second- or third-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, in advanced NSCLC as salvage treatment. We evaluated the efficacy and toxicity of apatinib in patients with previously treated advanced NSCLC from 2014 to 2015 in Zhejiang Cancer Hospital. Survival analysis was performed by the Kaplan-Meier method. Forty-two patients were included in the present study. Four patients achieved partial response, and 22 achieved stable disease, representing a response rate of 9.5% and a disease control rate of 61.9%. Median progression-free survival and overall survival were 4.2 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%. Apatinib appears to have some activity against advanced NSCLC when utilized as salvage treatment.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S113435